At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 558 enrolled
Drug / intervention
ABP 710 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis
In Brief
A Phase 3 clinical trial evaluating ABP 710 and Infliximab for Arthritis, Rheumatoid. Completed, enrolled 558 participants across 73 sites in 9 countries.
Detailed Summary
The main purpose of the study was to compare rheumatoid arthritis symptom improvement in participants who were given ABP 710 to those who were given infliximab, 22 weeks after starting treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesAustralia, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedOct 2016
Primary CompletionApr 2018
Study CompletionAug 2018
TodayJul 2026
First PostedOct 19, 2016
Enrollment StartOct 10, 2016
Primary CompletionApr 16, 2018
Study CompletionAug 13, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.7 years ago
Interventions
ABP 710biological
Administered by intravenous infusion
Infliximabbiological
Administered by intravenous infusion